Objective: Ectopic pregnancy case fatalities have decreased dramatically, although incidence has remained steady over years. Advancement in early diagnosis methods and intro duction of methotrexate (MTX) in the management has led to such improve ment. Different protocols, such as single, two dose and multiple doses of MTX has been indorsed by the American congress of obstetrics and gynecology. Here at Women's Hospital in Qatar we use single dose pro tocol. However, there no previous report on the outcome of MTX in term success rate in Qatar.
InTRODuCTIOn
The last three decades have witnessed 6 fold increases in ectopic pregnancy rates (comprising 2% of all preg nancies), Nevertheless, there was a dramatic decrease in the case fatalities from 35.5 per 10,000 in 1970s to 3.8 per 10,000.
1,2 A progress that has been attributed to the introduction of early diagnosis with transvaginal ultrasound, serial bhCG, and the improvement in anes thesia field, antibiotics availability, blood transfusion and introduction of methotrexate (MTX) injection at the earliest 1970th. 3, 4 Moreover, introduction of medical management with MTX injection has improved post treatment patient physical activity and decreased hospital stay and cost of treatment especially in patients with serum bhCG < 1500 IU/L. 5, 6 Different protocols have been developed since the introduction of MTX in the management of ectopic preg nancy. Stovall et al had demonstrated successful management with single dose MTX injection (50 mg/m 2 ). 5 Thereafter, international obstetric and gyne cologic societies has adopted this protocol and recommended its use. 7, 8 While it has high success rate this protocol require the patient to have presented with unruptured ectopic pregnancy of a size < 3.5 cm, bhCG < 5000 IU/L (RCOG) and 3500 IU/L (ACOG), hemodynamically stable with no known blood dys cariases, not known to have any chronic liver, renal and lung diseases and to be committed for follow up as scheduled. If a patient fall in this criteria will be considered for MTX injection and will be followed by their bhCG level on day 4, 7 and then weekly. A decrease of 15% between any two points were deemed a positive marker, otherwise a second dose of MTX is prescribed if the patient is stable or will be posted for DSJUOG surgical intervention. Patients are considered successfully treated and discharged from followup when their bhCG hormone become undetectable (bhCG < 5 IU/L). 7, 8 Methotrexate had been used for a long time in Women's Hospital in Qatar, and to date there is no study that has been conducted to find out the success rate of MTX injec tion when used for the management of ectopic pregnancy in Qatar population. Hence, we conducted a retrospective study in our institution.
METHODS
Ethical approval for this study was obtained from Medical Research Center, Hamad Medical Corporation, Qatar under research protocol number 11149/11.
We conducted a retrospective analysis of all women who received MTX for tubal ectopic pregnancy (EP) between Jan 2008 and Dec 2010. Patients excluded from the study were those with ectopic pregnancy of other locations and patients who received MTX for other reasons.
A list of the patients who received MTX during the study period was generated from the pharmacy manage ment system, then patient's files were reviewed and screened for inclusion and exclusion criteria and data was recorded in a predesigned recording observation form. After data collection completion, random files were selected and reviewed by a second person (PI) to ensure correct ness of recorded data on the data observation form in order to ensure validity of the read data values.
Outcome Evaluation Criteria
For the purpose of this study, the following were defined as: • Baseline bhCG: bhCG level collected within 24 hours before MTX injection; any samples of bhCG collected more than 24 hours prior to injection is considered as a missing value. 
Statistical Analysis
Categorical and continuous data expressed as frequency (percentage) and mean ± SD. Descriptive statistics used to summarize all demographic and clinical characteristics of the patients. Quantitative variables means between the two independent groups were analyzed using unpaired 't' test. Changes in the mean scores for different quantitative variables at different time points were assessed and compared using repeated measure ANOVA. Pictorial presentations of the key results were made using appropriate statistical graphs. A twosided pvalue < 0.05 was considered statistically significant. All statistical analyses were done using SPSS 19.0 (SPSS, Chicago).
RESulTS
We had 259 patients received MTX during the study period. Seven patients received MTX for other reasons and four files were not accessible. Therefore, 248 patients were included and their demographic data and clinical characteristics were tabulated (Flow Chart 1).
Majority of the patients were Qatari (34%) followed by Indians (15%). The gestational age at the time of diagnosis was 6 weeks ( Table 1) .
During our study period, MTX prescribing has increased 3 times in 2010 compared to 2008. Sixty percent of the patient received proper dose of MTX. In total, 79% completed their followup. Mean baseline bhCG level was 2486 IU/L (11% had baseline bhCG between 3000 and 5000 IU/L and 14% of the patients had baseline bhCG ≥ 5000 IU/L). Of note, six patients received MTX with baseline bhCG level > 10000 IU/L.
Since, only 196 patients completed their followup. Subse quent analysis is based on these patients. Eighty nine percent were successfully managed with MTX injection without further surgical intervention. Whilst 78% received one dose, 11% received two or three doses. All these were then followed until theirs bhCG become < 15 IU/L. The followup duration ranged between 1 and 4 months. Fifty percent of the patients had their bhCG become < 15 IU/L in the first month and another 40% within 2 months. On the other hand, 11% of the patients started on MTX injection were treated surgically. Out of these, 72.2% had rupture, 16.7% had hormonal plateau and in 11.1% patients declined second dose of MTX. Based on the treatment given, patients were further stratified into three groups; those who received one dose, those who received more than one dose and those who were treated with MTX and surgical intervention. Then, it was analyzed according to; bhCG levels, MTX dose and patient compliance with followup.
Successful MTX outcome with single dose correlate positively with lower baseline level bhCG (p = 0.003) ( Table 2) . Furthermore, patients who responded to one dose of MTX showed continues decline of bhCG level over day 1, 4 and 7 (Graph 1). Higher number of patients had surgical removal of EP in the group who received high dose of MTX compared to patients who received proper dose (16.2% vs 8.8%). There was a significant association between patient successful outcome and patient compliance to proper followup on day 4 and 7 (p = 0.034) ( Table 2) .
Where reduction in day 4 and 7 bhCG were < 15%, 21% of the patient experienced medical treatment failure. While, a 15% decrease or more of bhCG level between day 4 and 7 revealed 97% success rate (Graph 2). Graph 2: βhCG decline between day 4 and 7 or day 1 and 4 as predictor for patient outcome. Group description: group 1: Decline in βhCG in day 4 and 7 <15%, group 2: decline in βhCG in day 1 and 4 <15% and decline in βhCG in day 4 and 7 >15%, group 3: decline in βhCG in day 1 and 4 >15% and decline in βhCG in day 4 and 7 >15% 9 Similarly, its use in our DSJUOG hospital has increased. This is probably due to increase awareness of its use and confidence in its efficacy among physicians and minimal side effects encountered by the patients. Moreover, in our case, there is also an increase in total number of EP. Which might be due to the increase in the number of women at reproductive age. This can be deduce from the fact that Qatar has seen an increase number of birth rate per annum during this period. A patient is deemed suitable for MTX injection if she met certain criteria such as; bhCG < 5000 IU/L, ectopic size < 3.5 cm, absence of fetal heart beats, and clinically stable. 7, 8 Ectopic size > 3.5 cm, initial bhCG level > 5000 IU/L and fetal cardiac activity is considered a relative contraindications due to decreased success rate. 10, 11 However, in such situations the management was left to the physician's discern and patient's pre ference. Moreover, the cost between MTX therapy and laparoscopic surgery in patients with bhCG below 1500 IU/L is comparable. 12 Since, the cost is not an issue to the patient in our institution (because it is a public run service), few patients with relative contraindications opted for MTX management to avoid survey and to preserve future pregnancy. We found higher number of patients who received high dose MTX end up with surgery. This might be because of presence of a relative contraindication, e.g. high bhCG, large ectopic size and viable ectopic pregnancy rather than a response to high dose of MTX. Management of patients with such relative contraindications presents a hurdle to healthcare providers. However, increasing the dose as seen in 35% of our patients does not increase the success rate (Table 2 ). In the view of this, it is advisable to use a multiple dose regimen as recommended by. 13 Comparing patients with bhCG below 5000 IU/L in our study, we found similar success rate when compared to other studies. 9 
COnCluSIOn AnD RECOMMEnDATIOn
Methotrexate is an effective method of treatment for ectopic pregnancy in stable patients. Days 4 and 7 bhCG is the most indicative of MTX success. Our study also found that increasing the dose more than 50 mg/m 2 does not improve patient's outcome in any of the patient categories. Methotrexate is also found to be effective in patient with baseline bhCG > 10000 IU/L, which has been contraindications to its use by many guidelines. Further studies is required to investigate the role of MTX in this group of patients. Strength of our study is a good number of patients reviewed, and generalizability of our study results on settings with the same practice and similar patient characteristics. On the other side, it is a retrospective data analysis. Hence, a larger number of patients will give a more robust data. Therefore, such a study is recommended. 
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